Pan-cancer analysis identifies KANSL2 as a cell-cycle–associated regulator of tumor progression and immunity in liver hepatocellular carcinoma
KANSL2 is identified as a key regulator of tumor progression and immune remodeling in LIHC and represents a promising biomarker for diagnosis and prognosis, and a potential therapeutic target.